From: Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
 | Univariable | Multivariable |  |  | |||
---|---|---|---|---|---|---|---|
Item | p value | HR | 95% CI | p value | Status | n (%) | |
Clinical | Lines of prior treatment | 0.0278 | 1.43 | 1.02–1.99 | 0.0360 | 0 | 18 (26) |
 | (adjuvant treatment as one line if applicable) |  |  |  |  | 1 | 25 (36) |
 |  |  |  |  |  | 2–3 | 13 (19) |
 |  |  |  |  |  | ≥ 4 | 13 (19) |
Mutation | PIK3CA | 0.0086 | 5.53 | 2.41–12.71 | 5.60E–05 | Mutated | 27 (39) |
 | PIK3CA or ERBB2 | 0.0100 |  |  |  |  |  |
 | CDK12 | 0.0135 | 3.47 | 1.12–10.73 | 0.0310 | Mutated | 9 (13) |
 | HMCN1 | 0.0200 |  |  |  |  |  |
 | CACNA1G | 0.0285 |  |  |  |  |  |
Signatures | DBS3 | 0.0009 | 18.07 | 5.71–57.17 | 8.50E−07 | > 10% contribution | 8 (12) |
 | SBS18 | 0.0210 |  |  |  |  |  |
 | SBS39 | 0.0239 |  |  |  |  |  |
 | SBS40 | 0.0417 |  |  |  |  |  |
 | SV6 | 0.0407 |  |  |  |  |  |
Copy numbers | Gain 8p11.23 | 0.0105 | 3.91 | 1.91–8.03 | 0.0002 | Present | 24 (35) |
 | WGD | 0.0286 |  |  |  |  |  |